These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32768644)

  • 1. Revisiting the hERG safety margin after 20 years of routine hERG screening.
    Leishman DJ; Abernathy MM; Wang EB
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and Clinical Utility of the hERG IC50:C
    Lehmann DF; Eggleston WD; Wang D
    Pharmacotherapy; 2018 Mar; 38(3):341-348. PubMed ID: 29380488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions.
    Leishman DJ; Brimecombe J; Crumb W; Hebeisen S; Jenkinson S; Kilfoil PJ; Matsukawa H; Melliti K; Qu Y
    J Pharmacol Toxicol Methods; 2024; 128():107524. PubMed ID: 38852689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized J to T peak and T peak to T end measurements in nonclinical species administered moxifloxacin and amiodarone.
    Bartko TM; Lutgen SM; Ross RA; Walisser JA; Garske EP; Kopelke KR; Ashcroft-Hawley K; Tang HM; Kremer JJ; Friedrichs GS; Nichols JV
    J Pharmacol Toxicol Methods; 2024; 128():107527. PubMed ID: 38852685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment.
    DI Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
    J Cardiovasc Electrophysiol; 2014 Feb; 25(2):197-207. PubMed ID: 24118558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
    Gintant G
    Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.
    Patel N; Hatley O; Berg A; Romero K; Wisniowska B; Hanna D; Hermann D; Polak S
    AAPS J; 2018 Mar; 20(3):47. PubMed ID: 29541956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR
    Novartis Found Symp; 2005; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with "Known Risk of Torsades de Pointes".
    Ryan K; Benz P; Zosel A; Farkas A; Theobald J
    Cardiovasc Toxicol; 2022 Sep; 22(9):866-877. PubMed ID: 35930218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of five positive control drugs in hERG external solution (buffer) by LC-MS/MS to support in vitro hERG assay as recommended by ICH S7B.
    King TI; Indapurkar A; Tariq I; DePalma R; Mistry S; Alvarez-Baron C; Ismaiel OA; Wu W; Chiu K; Patel V; Rouse R; Strauss DG; Matta MK
    J Pharmacol Toxicol Methods; 2022; 118():107229. PubMed ID: 36334898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project.
    Hazell L; Raschi E; De Ponti F; Thomas SH; Salvo F; Ahlberg Helgee E; Boyer S; Sturkenboom M; Shakir S
    J Clin Pharmacol; 2017 May; 57(5):558-572. PubMed ID: 28019033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
    Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
    J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
    Haddad PM; Anderson IM
    Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
    Sharifi M; Buzatu D; Harris S; Wilkes J
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.